ArticleApplied and environmental microbiology2015
Metabolic engineering of Escherichia coli for the synthesis of the plant polyphenol pinosylvin.
Article in Applied and environmental microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 94 citations in OpenAlex.
- Enhancing 3-hydroxypropionic acid production from recombinantSynthetic and systems biotechnology · 2025Article
- Pinosylvin: A Multifunctional Stilbenoid with Antimicrobial, Antioxidant, and Anti-Inflammatory Potential.Current issues in molecular biology · 2025Review
- Stilbenes: a journey from folklore to pharmaceutical innovation.Archives of microbiology · 2024Review
- Transcriptional and translational flux optimization at the key regulatory node for enhanced production of naringenin using acetate in engineered Escherichia coli.Journal of industrial microbiology & biotechnology · 2024Article
- AFrontiers in plant science · 2024Article
- Microbial production of nutraceuticals: Metabolic engineering interventions in phenolic compounds, poly unsaturated fatty acids and carotenoids synthesis.Journal of food science and technology · 2023Review
- Identification of Pinosylvin inPharmaceuticals (Basel, Switzerland) · 2023Article
- Efficient biosynthesis of pinosylvin from lignin-derived cinnamic acid by metabolic engineering of Escherichia coli.Biotechnology for biofuels and bioproducts · 2022Article
- A targeted metabolomics method for extra- and intracellular metabolite quantification covering the complete monolignol and lignan synthesis pathway.Metabolic engineering communications · 2022Article
- Optimum flux rerouting for efficient production of naringenin from acetate in engineered Escherichia coli.Biotechnology for biofuels and bioproducts · 2022Article
- Natural Sources and Pharmacological Properties of Pinosylvin.Plants (Basel, Switzerland) · 2022Review
- Biotechnological production of specialty aromatic and aromatic-derivative compounds.World journal of microbiology & biotechnology · 2022Review
- Engineered biosynthesis of plant polyketides by type III polyketide synthases in microorganisms.Frontiers in bioengineering and biotechnology · 2022Review
- Synthetic Biology-Driven Microbial Production of Resveratrol: Advances and Perspectives.Frontiers in bioengineering and biotechnology · 2022Review
- Identification and Characterization of an Efficient Phenylalanine Ammonia-Lyase from Photorhabdus luminescens.Applied biochemistry and biotechnology · 2021Article
- High-yield 'one-pot' biosynthesis of raspberry ketone, a high-value fine chemical.Synthetic biology (Oxford, England) · 2021Article
- A unified design allows fine-tuning of biosensor parameters and application across bacterial species.Metabolic engineering communications · 2020Article
- Engineering intracellular malonyl-CoA availability in microbial hosts and its impact on polyketide and fatty acid synthesis.Applied microbiology and biotechnology · 2020Review
- Resveratrol: A Fair Race Towards Replacing Sulfites in Wines.Molecules (Basel, Switzerland) · 2020Review
- Metabolic Engineering of Microorganisms for the Production of Flavonoids.Frontiers in bioengineering and biotechnology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plant polyphenols are of great interest for drug discovery and drug development since many of these compounds have health-promoting activities as treatments against various diseases, such as diabetes, cancer, or heart diseases. However, the limited availability of polyphenols represents a major obstacle to clinical applications that must be overcome. In comparison to the quantities of these compounds obtained by isolation from natural sources or costly chemical synthesis, the microbial production of these compounds could provide sufficient quantities from inexpensive substrates. In this work, we describe the development of an Escherichia coli platform strain for the production of pinosylvin, a stilbene found in the heartwood of pine trees which could aid in the treatment of various cancers and cardiovascular diseases. Initially, several configurations of the three-step biosynthetic pathway to pinosylvin were constructed from a set of two different enzymes for each enzymatic step. After optimization of gene expression and evaluation of different construct environments, low pinosylvin concentrations up to 3 mg/liter could be detected. Analysis of the precursor supply and a comparative analysis of the intracellular pools of pathway intermediates and product identified the limited malonyl coenzyme A (malonyl-CoA) availability and low stilbene synthase activity in the heterologous host to be the main bottlenecks during pinosylvin production. Addition of cerulenin for increasing intracellular malonyl-CoA pools and the in vivo evolution of the stilbene synthase from Pinus strobus for improved activity in E. coli proved to be the keys to elevated product titers. These measures allowed product titers of 70 mg/liter pinosylvin from glucose, which could be further increased to 91 mg/liter by the addition of l-phenylalanine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.